In PCa cells, the activation of GLP-1-R triggers the cAMP cascade, inhibiting extracellular-signal-regulated kinases (ERK) and Cyclin D1, essential for DNA replication and cell cycle progression
Recent studies have shown that the use of GLP-1 agonists is associated with higher rates of gastroparesis, intestinal blockages and pancreatitis
Economic modeling in patients with obesity and knee osteoarthritis suggests that both semaglutide and tirzepatide would generally be considered cost-effective compared with usual care, with tirzepatide offering the more favorable return on investment once willingness-to-pay thresholds exceed $57,400 per QALY ( 9 Conclusion GLP-1 receptor agonists have expanded the therapeutic discussion in obesity-related knee osteoarthritis by making substantial pharmacologic weight loss achievable for selected patients
Together, they unpack what food noise really means and what gets lost when legitimate physiological and psychological hunger is pathologized for profit
For maintenance-level treatments at 0.25 mm, a dermaroller works fine and costs a fraction of the price
At the same time, supportive regulatory approvals and growing healthcare coverage are facilitating wider market penetration while pharmaceutical innovations like oral formulations and longer-acting injectables are improving patient convenience and compliance